Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Healthy volunteers to test how new drug enters the body

NCT ID NCT07545590

First seen May 02, 2026 · Last updated Jun 20, 2026 · Updated 10 times

Summary

This early-stage study will test how eltrekibart, an experimental drug, is absorbed when injected under the skin compared to when given through a vein. Sixty healthy adults will receive a single dose and be monitored for about 17 weeks. The goal is to gather safety and absorption data, not to treat any disease.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Lilly Centre for Clinical Pharmacology

    Singapore, 138623, Singapore

    Contact Phone: •••-•••-••••

    Contact

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

eltrekibart (LY3041658)

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.